TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02875925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM
Description: Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
Study: NCT03175432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT00640341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision Contact Lens
Description: contact lens for daily wear
Study: NCT03175432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04536831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D will be given to group A selected by Lottery method

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Vitamin D will be given to group B slected by Lottery method
Study: NCT00346944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of dental amalgam restorations
Description: Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
Study: NCT01763671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01354067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
Study: NCT01354067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-repetitive single limb training
Description: The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
Study: NCT00640341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Contact Lens
Description: contact lens for daily wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2Optix Contact lens
Description: contact lens for daily wear
Study: NCT06353724

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning
Description: Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment.
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules
Study: NCT00573196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far infrared
Description: Far infrared radiation (5μm to 15μm wavelength)
Study: NCT00048061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate [Bonviva/Boniva]
Description: 2.5mg po daily
Study: NCT06353724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital positioning stent
Description: Digital positioning stent
Study: NCT04258709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AME
Description: Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video-based infant care education
Description: Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
Study: NCT06111534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
Study: NCT01513044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 250 mg capsules of Roche Laboratories Inc.
Study: NCT00048061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 100mg po monthly on a single day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 100mg po monthly over 2 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate [Bonviva/Boniva]
Description: 150mg po monthly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 500 mg/day
Study: NCT03397667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABC ANSWERS
Description: Primary Care plus ABC ANSWERS
Study: NCT00048061

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 500 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 500 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 500 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU/day
Study: NCT03560830

Intervention type: OTHER
Intervention: 2 submaximal exercise stress tests
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules
Study: NCT03560830

Intervention type: OTHER
Intervention: 2 submaximal exercise stress tests

Intervention type: OTHER
Intervention: 2 submaximal exercise stress tests

Intervention type: OTHER
Intervention: 2 submaximal exercise stress tests
Study: NCT03397667

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Primary Care as usual
Study: NCT05998980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Componeer prefabricated veneers
Description: Individual Randomized Clinical Trial
Study: NCT01902251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide tablet
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide capsule
Description: Oral
Study: NCT01346917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
Study: NCT04005170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Cisplatin
Description: Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
Study: NCT01292785

Intervention type: DRUG
Intervention: Hormones
Description: FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss.
Study: NCT05959603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
Study: NCT05998980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Essentia resin composite veneers
Description: Individual Randomized Clinical Trial
Study: NCT04494321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study: NCT03878082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol 1g
Description: pain control with IVPCA and propacetamol 1g every 6 hours for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propacetamol 2g
Description: pain control with IVPCA and propacetamol 2g every 6 hours for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IVPCA
Description: pain control with IVPCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVPCA
Description: pain control with IVPCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVPCA
Description: pain control with IVPCA
Study: NCT02445443

Intervention type: DEVICE
Intervention: LEGION Hinge Knee System
Description: All enrolled/treated subjects will receive the LEGION Hinge Knee System.
Study: NCT03353389

Intervention type: OTHER
Intervention: No AKI
Description: Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.

Intervention type: OTHER
Intervention: CA-AKI
Description: CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown.

Intervention type: OTHER
Intervention: HA-AKI
Description: HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown.
Study: NCT04640181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin While hospitalized only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
Study: NCT01362751

Intervention type: OTHER
Intervention: No intervention
Description: This study is an observational cohort study \> no interventions
Study: NCT00107952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day IV for up to 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV q 12 hrs for up to 21 days
Study: NCT03792243

Intervention type: PROCEDURE
Intervention: Complication
Description: Readmission, reoperation
Study: NCT02008578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous hyperimmune immunoglobulin (Flu-IVIG)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01296243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
Study: NCT02679768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Reinforcement Therapy
Description: Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment plus electronical monitoring
Study: NCT03679585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Undergo Talking Pictures social media intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01388920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01775462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI200
Description: 3 or 10 mg/kg of EDI200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI200
Description: 3 or 10 mg/kg of EDI200
Study: NCT05319769

Intervention type: PROCEDURE
Intervention: Atrial fibrillation ablation
Description: Pulmonary vein isolation

Intervention type: PROCEDURE
Intervention: Atrial fibrillation ablation
Description: Pulmonary vein isolation
Study: NCT02467335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068
Study: NCT02462083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT01361815

Intervention type: DEVICE
Group type: OTHER
Intervention: H-Coil Deep TMS in combination with SSRIs
Description: The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
Study: NCT02711995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RenuGel
Description: Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
Study: NCT04176614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cereal-legume snack
Description: cereal-legume biscuit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cereal snack
Description: cereal biscuit
Study: NCT02018861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study: NCT02018861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Study: NCT02272023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Motivational Interviewing
Description: Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session of Motivational Interviewing
Study: NCT00115180

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention